Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Emerald Advisers LLC

Emerald Advisers LLC cut its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 2.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 392,591 shares of the biopharmaceutical company’s stock after selling 9,020 shares during the period. Intra-Cellular Therapies makes up approximately 1.1% of Emerald Advisers LLC’s holdings, making the stock its 29th biggest position. Emerald Advisers LLC owned about 0.37% of Intra-Cellular Therapies worth $26,889,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. Emerald Mutual Fund Advisers Trust lifted its position in shares of Intra-Cellular Therapies by 0.6% during the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 314,051 shares of the biopharmaceutical company’s stock valued at $21,509,000 after acquiring an additional 1,920 shares during the last quarter. General American Investors Co. Inc. raised its position in shares of Intra-Cellular Therapies by 0.5% during the second quarter. General American Investors Co. Inc. now owns 261,780 shares of the biopharmaceutical company’s stock worth $17,929,000 after purchasing an additional 1,341 shares during the period. Arizona State Retirement System lifted its holdings in shares of Intra-Cellular Therapies by 2.6% during the second quarter. Arizona State Retirement System now owns 24,412 shares of the biopharmaceutical company’s stock valued at $1,672,000 after purchasing an additional 608 shares during the last quarter. Victory Capital Management Inc. boosted its position in shares of Intra-Cellular Therapies by 7.4% in the 2nd quarter. Victory Capital Management Inc. now owns 68,139 shares of the biopharmaceutical company’s stock valued at $4,667,000 after purchasing an additional 4,674 shares during the period. Finally, Privium Fund Management B.V. increased its stake in Intra-Cellular Therapies by 8.4% in the 2nd quarter. Privium Fund Management B.V. now owns 117,983 shares of the biopharmaceutical company’s stock worth $8,087,000 after purchasing an additional 9,100 shares in the last quarter. 92.33% of the stock is currently owned by institutional investors.

Intra-Cellular Therapies Price Performance

NASDAQ ITCI opened at $73.54 on Friday. Intra-Cellular Therapies, Inc. has a fifty-two week low of $45.50 and a fifty-two week high of $84.89. The stock’s 50-day moving average is $75.08 and its two-hundred day moving average is $71.16. The firm has a market cap of $7.76 billion, a P/E ratio of -63.40 and a beta of 1.00.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.03. Intra-Cellular Therapies had a negative return on equity of 11.48% and a negative net margin of 14.93%. The business had revenue of $161.40 million for the quarter, compared to the consensus estimate of $157.74 million. During the same period last year, the business earned ($0.45) EPS. The firm’s revenue was up 45.7% compared to the same quarter last year. On average, equities analysts expect that Intra-Cellular Therapies, Inc. will post -0.59 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Canaccord Genuity Group boosted their target price on shares of Intra-Cellular Therapies from $107.00 to $113.00 and gave the company a “buy” rating in a research note on Thursday, June 20th. Royal Bank of Canada dropped their target price on Intra-Cellular Therapies from $107.00 to $106.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Mizuho raised their price target on shares of Intra-Cellular Therapies from $96.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, June 21st. UBS Group lowered their price objective on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Finally, JPMorgan Chase & Co. increased their target price on shares of Intra-Cellular Therapies from $79.00 to $81.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $96.58.

Insider Activity

In related news, CEO Sharon Mates sold 34,396 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $72.84, for a total transaction of $2,505,404.64. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at approximately $77,962,764.36. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, EVP Mark Neumann sold 18,714 shares of the firm’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $75.08, for a total value of $1,405,047.12. Following the sale, the executive vice president now directly owns 29,700 shares of the company’s stock, valued at $2,229,876. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Sharon Mates sold 34,396 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $72.84, for a total value of $2,505,404.64. Following the transaction, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at approximately $77,962,764.36. The disclosure for this sale can be found here. Insiders have sold a total of 199,778 shares of company stock valued at $14,892,738 over the last 90 days. 3.40% of the stock is currently owned by company insiders.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.